Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 1Phase 2/3 1Phase 1 1

Status

Unknown 7Withdrawn 1

Sponsor Class

OTHER 8

Study Type

Interventional 8

Sponsor

Cancer Type

Thoracic 8

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 8Brain Neoplasms 3Rare Tumor 1Radiation Pneumonitis 1Liver Diseases 1Digestive System Diseases 1Aumolertinib 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × aumolertinib × Clear all
NCT06227897 2024-12-10

AERESA

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT04808752 2024-04-22

ACHIEVE

Zhejiang Cancer Hospital

Phase 2 Unknown
63 enrolled
Thoracic

Lung Neoplasms

NCT05946460 2024-02-06

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Unknown
22 enrolled
Thoracic

Lung Neoplasms

NCT04922138 2023-04-21

APPOINT

Shanghai Chest Hospital

Phase 2 Unknown
104 enrolled
Thoracic

Lung Neoplasms

NCT04519983 2023-03-20

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Shanghai Cancer Hospital, China

Phase 2 Unknown
40 enrolled
Thoracic

Lung Neoplasms

NCT04882345 2021-05-11

ACTIVE

Shanghai Chest Hospital

Phase 2 Unknown
40 enrolled
Thoracic

Lung Neoplasms

NCT04636593 2021-01-12

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

First People's Hospital of Hangzhou

Phase 2 Unknown
43 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Pneumonitis

NCT04592666 2020-10-19

APPEAL

Fudan University

Phase 2 Unknown
226 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡